鹭燕医药
(002788)
| 流通市值：42.39亿 | | | 总市值：43.13亿 |
| 流通股本：3.82亿 | | | 总股本：3.89亿 |
| 利润表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 营业总收入 | 10,582,518,010.94 | 5,351,016,756.02 | 21,246,784,960.41 | 15,855,458,775.65 |
| 营业总成本 | 10,388,209,566.95 | 5,255,140,222.71 | 20,837,598,561.52 | 15,546,321,924.06 |
| 其他经营收益 | | | | |
| 营业利润 | 187,716,952.76 | 90,351,984.93 | 378,877,257.76 | 289,762,346.99 |
| 利润总额 | 188,980,850.72 | 90,191,693.27 | 376,227,006.93 | 288,256,227.69 |
| 净利润 | 139,814,750.35 | 66,042,039.33 | 278,981,375.38 | 218,463,133.91 |
| 每股收益 | | | | |
| 其他综合收益 | -717,821.01 | -423,243.83 | -420,906.77 | -202,411.95 |
| 综合收益总额 | 139,096,929.34 | 65,618,795.5 | 278,560,468.61 | 218,260,721.96 |
| 资产负债表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 流动资产: | | | | |
| 流动资产合计 | 10,258,235,818.08 | 10,416,210,733.43 | 10,457,619,701.96 | 10,179,743,761 |
| 非流动资产: | | | | |
| 非流动资产合计 | 2,930,147,433.22 | 2,924,715,114.32 | 2,938,112,309.85 | 2,862,542,113.25 |
| 资产总计 | 13,188,383,251.3 | 13,340,925,847.75 | 13,395,732,011.81 | 13,042,285,874.25 |
| 流动负债: | | | | |
| 流动负债合计 | 9,290,389,943.45 | 9,411,247,021.93 | 9,582,358,181.52 | 9,262,549,751.26 |
| 非流动负债: | | | | |
| 非流动负债合计 | 571,174,397.85 | 539,982,548.53 | 489,296,348.5 | 515,958,387.84 |
| 负债合计 | 9,861,564,341.3 | 9,951,229,570.46 | 10,071,654,530.02 | 9,778,508,139.1 |
| 所有者权益(或股东权益): | | | | |
| 归属于母公司股东权益合计 | 3,313,294,867.44 | 3,374,499,458.1 | 3,306,986,241.91 | 3,240,052,429.22 |
| 股东权益合计 | 3,326,818,910 | 3,389,696,277.29 | 3,324,077,481.79 | 3,263,777,735.15 |
| 负债和股东权益合计 | 13,188,383,251.3 | 13,340,925,847.75 | 13,395,732,011.81 | 13,042,285,874.25 |
| 现金流量表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 经营活动产生的现金流量: | | | | |
| 经营活动现金流入小计 | 12,088,425,912.76 | 5,926,800,501.8 | 22,985,063,494.54 | 17,188,720,589.84 |
| 经营活动现金流出小计 | 12,189,534,946.67 | 6,176,768,064.31 | 22,296,663,356.02 | 16,859,017,711.09 |
| 经营活动产生的现金流量净额 | -101,109,033.91 | -249,967,562.51 | 688,400,138.52 | 329,702,878.75 |
| 投资活动产生的现金流量: | | | | |
| 投资活动现金流入小计 | 3,391,242.46 | 22,459.2 | 834,220.96 | 832,458.48 |
| 投资活动现金流出小计 | 79,254,596.24 | 42,260,792.18 | 244,409,535.74 | 194,330,403.64 |
| 投资活动产生的现金流量净额 | -75,863,353.78 | -42,238,332.98 | -243,575,314.78 | -193,497,945.16 |
| 筹资活动产生的现金流量: | | | | |
| 筹资活动现金流入小计 | 5,386,999,574.85 | 3,040,170,843.1 | 9,501,113,716.13 | 7,320,652,703.46 |
| 筹资活动现金流出小计 | 5,105,130,724.56 | 2,762,059,545.5 | 9,941,197,180.05 | 7,563,325,951.81 |
| 筹资活动产生的现金流量净额 | 281,868,850.29 | 278,111,297.6 | -440,083,463.92 | -242,673,248.35 |
| 汇率变动对现金及现金等价物的影响 | -393,081.99 | -227,983.98 | -465,899.86 | -396,890.77 |
| 现金及现金等价物净增加额 | 104,503,380.61 | -14,322,581.87 | 4,275,459.96 | -106,865,205.53 |
| 期末现金及现金等价物余额 | 449,703,744.81 | 330,877,782.33 | 345,200,364.2 | 234,059,698.71 |
| 补充资料: | | | | |
| 现金及现金等价物的净增加额 | 104,503,380.61 | - | 4,275,459.96 | - |